Appropriate Patient Selection for Talquetamab in Relapsed/Refractory MM

Considerations for the integration of GPRC5-targeted therapy into the real-world treatment paradigm of relapsed/refractory multiple myeloma.

Related Videos
Experts on RCC
Experts on RCC
Experts on multiple myeloma
Experts on multiple myeloma
Experts on RCC
Experts on RCC
Related Content